3Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients[J]. J Clin Oncol, 2004, 22(9):1646-1654.
4Crombet-Ramos T, Rak J, P6rez R, et al. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody [J]. lnt J Cancer, 2002, 101 (6):567-575.
4TUT V M, BRAITHWAITE K L, ANGUS B, et al. CyclinD1 expression in transitional cell carcinoma of the bladder: correlation with p53, wsfl, PRb and Ki67 [ J]. Brit J Cancer, 2001, 84 (2) : 270.
5DUDEK A, MAHASETH H. Circulating angiogenic cytokines in patients with advanced non - small cell lung cancer: correlation with treatment response and survival [ J ]. Cancer Investig, 2005, 3:193-200.
6CHOI J, KIM H, LIM H, et al. Vascular end othelial growth factor in the serum of patients with non - small cell lung cancer: correlation with platelet and leukocyte ounts [ J ]. Lung Cancer, 2001, 33 : 171 - 179.
7ZHENG X, HU L, CHEN F, et al. Expression of Ki67 antigen, epidermal growth factor recept Epstein Barr virus - en - code latent membrane protein ( Lmpl ) nasopharyngeal carcinoma [ J ]. Eur J Cancer B Oral Oncol, 1994, 3 031 (5): 290-295.
8ROYCHOWDHURY D F, ALEXANDER T J, KAREN K F, et al. New prognostic factors in nasopharyngeal carcinoma[J]. Cancer, 1996, 77:1 419 -1 426.
9LASKIN J J, SANDLER A B. EpMermM growth factor receptor: a promising target in solid tumors[J]. J Cancer Treat Rev, 2004, 30(1) : 1 -17.
